[go: up one dir, main page]

NO981810L - Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt - Google Patents

Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt

Info

Publication number
NO981810L
NO981810L NO981810A NO981810A NO981810L NO 981810 L NO981810 L NO 981810L NO 981810 A NO981810 A NO 981810A NO 981810 A NO981810 A NO 981810A NO 981810 L NO981810 L NO 981810L
Authority
NO
Norway
Prior art keywords
bone
ability
compositions
methods
failure conditions
Prior art date
Application number
NO981810A
Other languages
English (en)
Other versions
NO981810D0 (no
Inventor
Charles Petrie
Mark W Orme
Nand Baindur
Kirk G Robbins
Scott M Harris
Maria Kontoyianni
Laurence H Hurley
Sean M Kerwin
Gregory R Mundy
Original Assignee
Zymogenetics Inc
Osteoscreen Inc
Univ Texas At Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Osteoscreen Inc, Univ Texas At Austin filed Critical Zymogenetics Inc
Publication of NO981810D0 publication Critical patent/NO981810D0/no
Publication of NO981810L publication Critical patent/NO981810L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Forbindelser inneholdene to aromatiske systemer kovalentlig koblet gjennom en linker inneholdene en eller flere atomer, eller «linker» definert som inkluderende en kovalent binding per se for å plassere aromatiske systemer i en avstand på 1,5-lSÅ, som er effektive for behandling av tilstander assosiert med bensvikt. Forbindelsene kan bli administrert til virveldyr, mennesker alene eller i kombinasjon med ytterligere midler som fremmer benvekst eller som inhiberer benresorpsjon. De kan bli screenet for aktivitet før administrering ved å vurdere deres evne til å påvirke transkripsjon av et reportergen koblet til en promoter assosiert med et benmorfogenisk protein og/eller deres evne til å stimulere hodeskalleveksten i dyremodellsystemer.
NO981810A 1995-10-23 1998-04-22 Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt NO981810L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US583095P 1995-10-23 1995-10-23
PCT/US1996/017019 WO1997015308A1 (en) 1995-10-23 1996-10-23 Compositions and methods for treating bone deficit conditions

Publications (2)

Publication Number Publication Date
NO981810D0 NO981810D0 (no) 1998-04-22
NO981810L true NO981810L (no) 1998-06-22

Family

ID=21717974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981810A NO981810L (no) 1995-10-23 1998-04-22 Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt

Country Status (13)

Country Link
EP (1) EP0866710A4 (no)
JP (1) JP2000513324A (no)
KR (1) KR19990067010A (no)
CN (1) CN1201393A (no)
AU (1) AU706262B2 (no)
BR (1) BR9611210A (no)
CA (1) CA2235481A1 (no)
CZ (1) CZ115398A3 (no)
EA (1) EA199800393A1 (no)
HU (1) HUP9802319A3 (no)
NO (1) NO981810L (no)
PL (1) PL327617A1 (no)
WO (1) WO1997015308A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2258822A1 (en) 1996-06-20 1997-12-24 Sean Kerwin Compounds and methods for providing pharmacologically active preparations and uses thereof
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
AU8748798A (en) * 1997-08-22 1999-03-16 Kyowa Hakko Kogyo Co. Ltd. 4-aminoquinazoline derivatives
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
DE19812204A1 (de) * 1998-03-19 1999-11-04 Plantamed Arzneimittel Gmbh Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung
JP2000004882A (ja) * 1998-06-18 2000-01-11 Hoechst Marion Roussel Kk ヒトｍｐ５２遺伝子プロモーターおよびこれを用いた有用物質の探索法
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
SK5282001A3 (en) * 1998-11-06 2002-01-07 Knoll Gmbh Tricyclic pyrazole derivatives
US6462036B1 (en) 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
WO2000078351A1 (en) * 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
WO2001017562A1 (fr) * 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
AU776933B2 (en) 1999-12-28 2004-09-23 Eisai R&D Management Co., Ltd. Heterocyclic compounds having sulfonamide groups
FR2806408B1 (fr) * 2000-03-17 2002-10-11 Oreal Composition cosmetique comprenant un derive de furane- naphtoquinone, leur utilisation comme agent colorant et derives
DE50108588D1 (de) 2000-06-05 2006-02-02 Austria Wirtschaftsserv Gmbh Heterocyclische Hydrazone als anti-Krebs-Wirkstoffe
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
AU2003220935A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
EP1547996A4 (en) * 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN
AU2003284492A1 (en) 2002-12-16 2004-07-09 Bf Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
ATE551324T1 (de) 2003-02-03 2012-04-15 Janssen Pharmaceutica Nv Chinolin-amid-derivate als modulatoren von vanilloid-vr1-rezeptoren
MXPA06012333A (es) 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
EP1856126A2 (en) 2005-02-17 2007-11-21 Wyeth a Corporation of the State of Delaware Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
CN101641339B (zh) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
WO2009076792A1 (en) 2007-12-19 2009-06-25 Givaudan Sa Cooling compounds
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
AU2010224523B2 (en) 2009-03-18 2014-05-08 Resverlogix Corp. Novel anti-inflammatory agents
MX374414B (es) 2009-04-22 2025-03-06 Resverlogix Corp Nuevos agentes anti-inflamatorios.
SI2773354T1 (sl) 2011-11-01 2019-08-30 Resverlogix Corp. Peroralne formulacije s takojšnjim sproščanjem za substituirane kinazolinone
US9388138B2 (en) 2012-07-18 2016-07-12 University College Dublin National University Of Ireland, Dublin Anti-angiogenic compounds
CN102942515A (zh) * 2012-10-22 2013-02-27 暨南大学 一种乙烯桥连吲哚化合物及其合成方法和用途
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CN105073744B (zh) 2012-12-21 2019-11-08 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新型杂环化合物
CN107530356A (zh) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
CN107019687B (zh) * 2017-05-08 2020-10-27 上海市伤骨科研究所 N-(4-氯苯基)-3-羟基-2-萘甲酰胺类化合物的用途
CN111116552B (zh) * 2020-01-17 2022-10-11 河北科技大学 一种喹唑啉酮类化合物及其制备方法
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用
CN116650481B (zh) * 2021-12-10 2024-06-14 中南大学湘雅医院 芳香族化合物作为神经丛素蛋白-b2的激活剂以及在制备治疗骨质疏松症药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JP2724396B2 (ja) * 1987-12-18 1998-03-09 武田薬品工業株式会社 骨粗鬆症予防治療剤
EP0536119A4 (en) * 1989-02-10 1993-08-04 Washington Research Foundation Immunoregulatory agents
JPH06192272A (ja) * 1992-12-24 1994-07-12 Japan Tobacco Inc 新規なトリアゾロベンゾチアジアジン及びトリアゾロベンゾチアジアゼピン誘導体
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
EP0716086A1 (en) * 1994-12-09 1996-06-12 Boehringer Mannheim Gmbh Malonic acid based matrix metalloproteinase inhibitors
AU4988997A (en) * 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
EP0944312B9 (en) * 1996-12-13 2006-07-05 ZymoGenetics, Inc. Compositions and methods for stimulating bone growth

Also Published As

Publication number Publication date
NO981810D0 (no) 1998-04-22
CN1201393A (zh) 1998-12-09
BR9611210A (pt) 1999-12-28
HUP9802319A3 (en) 1999-12-28
PL327617A1 (en) 1998-12-21
KR19990067010A (ko) 1999-08-16
EP0866710A4 (en) 2001-07-11
WO1997015308A1 (en) 1997-05-01
JP2000513324A (ja) 2000-10-10
AU706262B2 (en) 1999-06-10
CZ115398A3 (cs) 1998-12-16
EA199800393A1 (ru) 1998-12-24
EP0866710A1 (en) 1998-09-30
CA2235481A1 (en) 1997-05-01
AU7471096A (en) 1997-05-15
HUP9802319A2 (hu) 1999-02-01

Similar Documents

Publication Publication Date Title
NO981810L (no) Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt
NO20043411L (no) Substituerte quinazolin-4-ylamin analoger
BR0010989A (pt) Plantas e células de plantas geneticamente modificadas com uma atividade aumentada de uma proteìna de amilossacarase e uma enzima de ramificação
PL328723A1 (en) Methods of and compositions for stimulating the growth of axons
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
WO2005009349A3 (en) Composition and method for treating neurological disorders
DK0861228T3 (da) Lipopolyaminer som transfektionsmidler samt deres farmaceutiske anvendelser
MXPA02005510A (es) Compuestos, composiciones y metodos para estimular el crecimiento y alargamiento neuronal.
BR0011394A (pt) Molécula, protéina purificada, ácido nucleico isolado, célula recombinante, métodos para produção de uma proteìna, para o tratamento ou prevenção de câncer e de um distúrbio imune e para ativação ou aumento da resposta imune em um indivìduo, animal não humano, planta ou uma célula isolada transgênicos, composição farmacêutica, e, anticporpo
AP2002002596A0 (en) Piperazine and piperidine derivatives.
Ben-Hur Involvement of poly (ADP-ribose) in the radiation response of mammalian cells
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ATE184883T1 (de) Muramylverbindungen zur behandlung von septischem schock
FI953369A7 (fi) Farmaseuttiset koostumukset syöpäsairauksien estämiseksi ja hoitamiseksi sekä menetelmä niiden valmistamiseksi
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
Yang et al. Kaempferol stimulates bone sialoprotein gene transcription and new bone formation
ATE289808T1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
WO2001021771A3 (en) Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
WO2001082952A3 (en) USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
Steeves et al. Engines, Accelerators, and Brakes on Functional Spinal Cord Repair a
NO20010940D0 (no) TAN-1057 derivater
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
NO985676L (no) Forbindelser med colchicinstruktur, deres anvendelse som legemidler og blan
PL376149A1 (en) Piperazine and piperidine derivatives for treatment of neurological diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application